If you follow biotech for any length of time, three acronyms keep surfacing, usually attached to a stock that just jumped or cratered: ASCO, ASH, and AACR. They are the big three oncology conferences, and they matter far beyond the cancer field because they are where some of the most consequential clinical data in all of medicine gets revealed. Here is what each one is and why the whole industry watches.
Why cancer has its own conference universe
Oncology is the largest and most active area of drug development, so it has grown an unusually rich ecosystem of scientific meetings. These are not partnering events like BIO; they are scientific congresses where researchers and companies present data, from early laboratory findings to pivotal trial results. Because a single data readout can make or break a program, and a company, these meetings function as scheduled catalysts that investors, executives, and clinicians plan their year around.
AACR: where the science starts
The American Association for Cancer Research meeting, held in spring, is the most science-forward of the three. It leans toward the earlier end of the pipeline: fundamental cancer biology, novel targets, translational research, and early clinical signals. If you want to see where oncology is heading in five years, AACR is where the seeds are visible. For investors, AACR data tends to be earlier and more preliminary, so it moves markets less violently than later-stage readouts, but it shapes the narrative about which approaches are gaining scientific momentum.
ASCO: where the clinic (and the market) reacts
The American Society of Clinical Oncology annual meeting, held around late spring in Chicago, is the giant of the three and arguably the most watched clinical event in all of medicine. Tens of thousands of oncologists and industry professionals gather, and the focus is squarely clinical: results from trials that could change how cancer is treated. ASCO is where practice-changing data lands, and it is the meeting most likely to send biotech stocks sharply up or down as pivotal results are presented. If you hear that a company is “presenting at ASCO,” it usually means clinical data with real commercial stakes.
ASH: blood cancers and beyond
The American Society of Hematology annual meeting, held in December, is the definitive event for hematology, the science and treatment of blood and blood cancers such as leukemia, lymphoma, and multiple myeloma, along with non-malignant blood disorders. Because so much cutting-edge work in cell therapy, gene therapy, and immuno-oncology runs through blood cancers first, ASH has become a major catalyst event in its own right, closing out the year with a wave of closely watched readouts. For anyone tracking cell and gene therapy, ASH is unmissable.
A quick word on ESMO and EHA
The big three are American societies, but the European calendar mirrors them. The European Society for Medical Oncology congress, held in autumn, is ASCO’s transatlantic counterpart and a major clinical catalyst, and the European Hematology Association congress plays a similar role to ASH for blood disorders. Global companies present at both the American and European meetings, so the oncology data calendar effectively runs year-round.
Why non-oncology people should still care
Even if you never touch cancer drugs, these meetings matter for three reasons. First, oncology is the leading edge of drug development, so the modalities that prove out in cancer, antibody-drug conjugates, bispecifics, cell therapies, often migrate to other diseases next. Second, the market reactions to this data set the tone for biotech sentiment as a whole; a strong ASCO can lift the mood across the sector. Third, the deals follow the data: a standout readout at ASCO or ASH frequently triggers the partnership and acquisition conversations that reshape the industry. Watching these meetings is watching where biotech is going.
How to actually follow the readouts
You do not have to attend to benefit. Abstracts are typically released ahead of each meeting, giving a preview of what will be presented, and the headline results are dissected in real time by industry media and analysts. The practical approach for most people is to skim the abstracts for the programs you care about, then follow trusted coverage during the meeting for the reactions and context. The signal is in which data beat expectations, which disappointed, and what the market and potential partners do next.
The bottom line
Think of it as a rhythm: AACR in spring for the science, ASCO in early summer for the practice-changing clinical data, ASH in December for blood cancers and advanced therapies, with the European congresses filling the gaps. Together they form the heartbeat of oncology drug development, and a surprising amount of the biotech year, from stock moves to M&A, is set to that beat. Learn to read it and a lot of the industry’s news stops feeling random.
How the data actually moves the industry
Part of what makes these congresses so powerful is a predictable rhythm around the data. Abstracts, the short summaries of what will be presented, are typically released ahead of each meeting, which triggers a first wave of analysis as investors and companies digest what is coming. Then the full results are presented at the meeting itself, often with more detail than the abstract revealed, and the second, larger reaction follows. Learning to read a readout is a genuine skill. The questions that matter are usually simple: did the drug hit its main goal, the primary endpoint; how big was the effect compared to the comparison group; and how did the safety profile look. A result that beats expectations can send a stock soaring and trigger partnership interest within hours; a disappointing one can erase a program overnight. This is why so many deals cluster around these meetings, a strong data readout is often the starting gun for the licensing and acquisition conversations that reshape the field. For anyone in the industry, the practical takeaway is to watch not just whether data is positive, but whether it beats what the market already expected, because expectations are usually priced in well before the presentation. The congresses, in other words, are less about the science in isolation and more about the collision between new evidence and existing assumptions, and that collision is what moves companies, valuations, and the direction of entire therapeutic areas.
Getting started if oncology is new to you
If you are newer to the field and want to start following these meetings, keep it simple at first. Pick the handful of companies or programs you actually care about and track only their presentations, rather than trying to absorb thousands of abstracts. Skim the abstract when it drops to understand what is being tested and what would count as a good result, then follow trusted industry coverage during the meeting for the interpretation and the market reaction. Over a few congress cycles, the rhythm becomes familiar, which drugs are being watched, which endpoints matter in which cancers, how analysts react, and you start to build the pattern recognition that makes the news legible. You do not need a medical degree to follow oncology data usefully; you need a short watchlist, a little patience, and the habit of asking whether each result beat, met, or missed what the market expected.
The habit that makes it click
If you take one practice away, make it this: for every readout you care about, decide in advance what a good result would look like before the data lands. Read the abstract, understand the main endpoint, and form a view on what would count as a beat, a miss, or a shrug. Then, when the results arrive, you are measuring reality against a considered expectation rather than reacting to a headline. This single habit, expectations first, data second, is what separates people who understand why a stock moved from people who are merely surprised by it, and it turns the congress calendar from a stream of confusing announcements into a legible, even predictable, rhythm you can plan around.
To keep the full oncology and scientific calendar in one view, the BioMed Nexus conferences directory tracks these congresses alongside every other major 2026 event, and the daily brief translates the key readouts into what they mean for companies, deals, and the sector as they happen.
Frequently asked questions
What is the difference between ASCO, ASH and AACR?
AACR focuses on earlier, more fundamental cancer science and novel targets; ASCO is the giant clinical oncology meeting where practice-changing trial data is presented; and ASH is the definitive hematology meeting covering blood cancers and disorders, including much of the leading work in cell and gene therapy.
Why do oncology conferences move biotech stocks?
These congresses are where pivotal clinical data is first revealed, and a single readout can validate or sink a drug program. Because the commercial stakes are enormous, results presented at ASCO or ASH frequently send biotech stocks sharply up or down and trigger partnership and acquisition activity.
When are ASCO, ASH and AACR held?
AACR is typically held in spring, ASCO around late spring in Chicago, and ASH in December. The European counterparts, ESMO for oncology and EHA for hematology, are held in autumn, so the oncology data calendar effectively runs throughout the year. Confirm exact dates on each society's site.
